James Abbruzzese, MD

Professor of Medicine
D. C. I. Distinguished Professor of Medical Oncology
Member of the Duke Cancer Institute
Campus mail 440 Mudd Building, Box 3406, Durham, NC 27710
Email address james.abbruzzese@duke.edu

My research interests include the clinical study and treatment of pancreatic cancer.

In Their Words

Education and Training

  • Resident, Internal Medicine, Johns Hopkins University School of Medicine, 1979 - 1981
  • Intern, Internal Medicine, Johns Hopkins University School of Medicine, 1978 - 1979
  • M.D., The University of Chicago, 1978

Publications

Weng, Shaofan, Hua Wang, Weihong Chen, Matthew H. Katz, Deyali Chatterjee, Jeffrey E. Lee, Peter W. Pisters, et al. “Overexpression of protein phosphatase 4 correlates with poor prognosis in patients with stage II pancreatic ductal adenocarcinoma.” Cancer Epidemiol Biomarkers Prev 21, no. 8 (August 2012): 1336–43. https://doi.org/10.1158/1055-9965.EPI-12-0223.

PMID
22665577
Full Text

Truty, Mark J., Ryan M. Thomas, Matthew H. Katz, Jean-Nicolas Vauthey, Christopher Crane, Gaury R. Varadhachary, Robert A. Wolff, James L. Abbruzzese, Jeffrey E. Lee, and Jason B. Fleming. “Multimodality therapy offers a chance for cure in patients with pancreatic adenocarcinoma deemed unresectable at first operative exploration.” J Am Coll Surg 215, no. 1 (July 2012): 41–51. https://doi.org/10.1016/j.jamcollsurg.2012.03.024.

PMID
22608401
Full Text

Chatterjee, Deyali, Matthew H. Katz, Asif Rashid, Gauri R. Varadhachary, Robert A. Wolff, Hua Wang, Jeffrey E. Lee, et al. “Histologic grading of the extent of residual carcinoma following neoadjuvant chemoradiation in pancreatic ductal adenocarcinoma: a predictor for patient outcome.” Cancer 118, no. 12 (June 15, 2012): 3182–90. https://doi.org/10.1002/cncr.26651.

PMID
22028089
Full Text

Dong, Xiaoqun, Yanan Li, Ping Chang, Kenneth R. Hess, James L. Abbruzzese, and Donghui Li. “DNA mismatch repair network gene polymorphism as a susceptibility factor for pancreatic cancer.” Mol Carcinog 51, no. 6 (June 2012): 491–99. https://doi.org/10.1002/mc.20817.

PMID
21681824
Full Text

Sadeghi, Navid, James L. Abbruzzese, Sai-Ching J. Yeung, Manal Hassan, and Donghui Li. “Metformin use is associated with better survival of diabetic patients with pancreatic cancer.” Clin Cancer Res 18, no. 10 (May 15, 2012): 2905–12. https://doi.org/10.1158/1078-0432.CCR-11-2994.

PMID
22465831
Full Text

Overman, Michael J., Chung-Yuan Hu, Scott Kopetz, James L. Abbruzzese, Robert A. Wolff, and George J. Chang. “A population-based comparison of adenocarcinoma of the large and small intestine: insights into a rare disease.” Ann Surg Oncol 19, no. 5 (May 2012): 1439–45. https://doi.org/10.1245/s10434-011-2173-6.

PMID
22187121
Full Text

Tomblyn, Michael B., Bryan H. Goldman, Charles R. Thomas, Jacqueline K. Benedetti, Heinz-Josef Lenz, Vivek Mehta, Thaddeus Beeker, et al. “Cetuximab plus cisplatin, irinotecan, and thoracic radiotherapy as definitive treatment for locally advanced, unresectable esophageal cancer: a phase-II study of the SWOG (S0414).” J Thorac Oncol 7, no. 5 (May 2012): 906–12. https://doi.org/10.1097/JTO.0b013e31824c7bed.

PMID
22481235
Full Text

Friday, Benjamin, Yvonne Lassere, Christina A. Meyers, Akira Mita, James L. Abbruzzese, and Melanie B. Thomas. “A phase I study to determine the safety and pharmacokinetics of intravenous administration of TAS-106 once per week for three consecutive weeks every 28 days in patients with solid tumors.” Anticancer Res 32, no. 5 (May 2012): 1689–96.

PMID
22593447
Scholars@Duke

Chang, David Z., Ying Ma, Baoan Ji, Yan Liu, Patrick Hwu, James L. Abbruzzese, Craig Logsdon, and Huamin Wang. “Increased CDC20 expression is associated with pancreatic ductal adenocarcinoma differentiation and progression.” J Hematol Oncol 5 (April 4, 2012): 15. https://doi.org/10.1186/1756-8722-5-15.

PMID
22475564
Full Text

Chatterjee, Deyali, Asif Rashid, Hua Wang, Matthew H. Katz, Robert A. Wolff, Gauri R. Varadhachary, Jeffrey E. Lee, et al. “Tumor invasion of muscular vessels predicts poor prognosis in patients with pancreatic ductal adenocarcinoma who have received neoadjuvant therapy and pancreaticoduodenectomy.” Am J Surg Pathol 36, no. 4 (April 2012): 552–59. https://doi.org/10.1097/PAS.0b013e318240c1c0.

PMID
22301496
Full Text

Pages